{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Rova-T/placebo, the patient may resume outdoor activities with appropriate sun protection', 'including broad brimmed hat, protective clothing and sunscreen SPF 30 or higher.', 'Section 5.2.3.2.1 Allowed Concomitant Therapy', 'First paragraph, third sentence previously read:', 'Bone modifying agents for bone metastases are also permitted per local institutional', 'standards.', 'Has been changed to read:', 'Bone modifying agents (e.g., bisphosphonates, denosumab) for bone metastases are also', 'permitted per local institutional standards.', 'Section 5.3.1.1 Study Procedures', 'Subsection Vital Signs', 'First paragraph, second sentence previously read:', 'Vital signs include weight, sitting blood pressure, heart rate and body temperature.', 'Has been changed to read:', 'Vital signs include actual weight, sitting blood pressure, heart rate and body temperature.', 'Section 5.3.1.1 Study Procedures', 'Subsection Vital Signs', 'Second paragraph previously read:', 'Weight will be collected in the clinic prior to dosing at each cycle and the recorded weight', 'will be utilized for dosing calculations. For weight assessments, the subject should not', 'wear shoes.', '169']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Has been changed to read:', 'Actual weight will be collected in the clinic prior to dosing at each cycle and the recorded', 'weight will be utilized for dosing calculations. For weight assessments, the subject', 'should not wear shoes. In the event of a 5% or greater increase in weight within', '2 consecutive visits or compared to baseline which ever has the shorter interval, a prompt', 'workup for fluid retention (e.g., edema, effusions, etc.) should be conducted. If weight', 'gain is due to proven or suspected fluid retention related to study drug, and dosing is not', 'prohibited per Section 5.5.4, dose should be calculated based on actual weight before the', 'event of fluid retention.', 'Section 5.3.1.1 Study Procedures', 'Subsection Echocardiogram', 'Previously read:', 'Echocardiograms will be performed per Appendix C, Study Activities to assess any', 'pericardial effusion, if present, as well as cardiac function (left ventricular ejection', 'fraction, LVEF).', 'Has been changed to read:', 'Echocardiograms will be performed per Appendix C, Study Activities to rule out', 'pericardial effusion (or assess, if present), as well as assess cardiac function (left', 'ventricular ejection fraction, LVEF).', 'Section 5.3.1.1 Study Procedures', 'Subsection Disease/Response Assessment (Radiographic Imaging)', 'Last paragraph previously read:', 'Scheduled tumor assessments will not be affected by delays in therapy and/or drug', 'holidays. Subjects will continue to be monitored by the same diagnostic method', 'throughout the study every 6 weeks after randomization, unless evidence of tumor', 'metastases warrants otherwise. Subjects who discontinue treatment for reasons other than', '170']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'radiographic disease progression will continue to be followed every 6 weeks from C1D1', 'to determine the extent of tumor burden, until disease progression occurs.', 'Has been changed to read:', 'Scheduled tumor assessments should not be affected by delays in therapy and/or drug', 'holidays. Subjects will continue to be monitored by the same diagnostic method', 'throughout the study every 6 weeks after randomization, unless evidence of tumor', 'progression warrants otherwise. In some cases, mandatory dose delays due to toxicity', 'will lead to a gap between tumor assessment and dosing. In cases where this gap exceeds', '1 week, the TAMD should be contacted for guidance.', 'Subjects who discontinue treatment for reasons other than radiographic disease', 'progression will continue to be followed every 6 weeks from randomization to determine', 'the extent of tumor burden, until disease progression occurs.', 'Section 5.3.1.1 Study Procedures', 'Subsection MRI/CT of the Brain', 'Last sentence previously read:', 'MRI/CT of the brain is only required at screening and when clinically indicated (e.g., if', 'CNS progression is suspected).', 'Has been changed to read:', 'MRI/CT of the brain is required at screening and when clinically indicated (e.g., if CNS', 'progression is suspected) thereafter.', 'Section 5.3.1.1 Study Procedures', 'Subsection Fluid Retention Questionnaire (Including Subject Daily Weight)', 'Last paragraph, last sentence previously read:', 'The site will advise subjects to contact the site in cases where sudden weight gain is', 'observed for possible assessment in the clinic.', '171']\n\n###\n\n", "completion": "END"}